港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

宝济药业-B

90.850

-1.350-1.46%

成交量：62.42万

成交额：5,684.79万

市值：296.15亿

市盈率：-11.79

高：93.150

开：92.250

低：90.150

收：92.200

52周最高：206.000

52周最低：56.000

股本：3.26亿

香港流通股本：1.54亿

量比：1.24

换手率：0.41%

股息：- -

股息率：- -

每股收益(LYR):-7.707

净资产收益率：--

总资产收益率：--

市净率：29.41

市盈率(LYR):-11.79

市销率: 560.66

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

宝济药业-B拟选举刘彦军、王政、李翠为执行董事

宝济药业(02659)2025年度业绩：核心管线快速推进，SJ02完成首批订单交付

《业绩》宝济药业(02659.HK)全年亏损扩大至3.95亿人币

阿斯达克财经

异动解读 | 新药进展伴随风险提示，宝济药业-B盘中大跌5.03%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02659"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":90.85,"timestamp":1774594716249,"preClose":92.2,"halted":0,"volume":624210,"delay":0,"changeRate":-0.014642082429501177,"floatShares":154000000,"shares":325981465,"eps":-7.706690642984139,"marketStatus":"交易中","change":-1.35,"latestTime":"03-27 14:58:51","open":92.25,"high":93.15,"low":90.15,"amount":56847890,"amplitude":0.032538,"askPrice":91.3,"askSize":1000,"bidPrice":90.8,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.44795722733503,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774599000000},"marketStatusCode":2,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":92.2,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":1.235922,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":154000000,"roa":"--","roe":"--","lyrEps":-7.706691,"volumeRatio":1.235922,"shares":325981465,"dividePrice":0,"high":93.15,"amplitude":0.032538,"preClose":92.2,"low":90.15,"week52Low":56,"pbRate":"29.41","psRate":"560.66","week52High":206,"institutionHeld":0,"latestPrice":90.85,"committee":-0.818182,"eps":-7.706690642984139,"divideRate":0,"volume":624210,"delay":0,"ttmEps":-1.44795722733503,"open":92.25,"prevYearClose":77.55,"prevWeekClose":93.65,"prevMonthClose":154.9,"prevQuarterClose":77.55,"fiveDayClose":93.65,"twentyDayClose":154.9,"sixtyDayClose":76.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1769184000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-03-25","current":-63.742818,"percent":0.614286,"low":-150.791275,"twenty":-108.900884,"median":-74.80362,"eighty":-57.965274,"high":-20.527356,"avg":-79.935684,"sd":26.676878,"marketCap":30039191999},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-25","current":-69.74185,"twenty":-108.900884,"median":-74.80362,"eighty":-57.965274,"marketCap":30039191999}],"updateTime":1774562606303},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1107635046","title":"宝济药业-B拟选举刘彦军、王政、李翠为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1107635046","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107635046?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:42","pubTimestamp":1774514562,"startTime":"0","endTime":"0","summary":"宝济药业-B近日宣布，公司计划选举刘彦军、王政及李翠担任执行董事职务。此次人事变动旨在优化公司治理结构，提升管理团队的决策效率与专业能力。\n刘彦军、王政和李翠均在医药行业拥有丰富的从业经验，他们的加入有望为宝济药业-B的战略发展注入新的活力。公司表示，这一举措将进一步加强董事会职能，推动业务持续稳健增长。\n市场观察人士指出，执行董事的调整可能影响公司未来的业务方向与资本市场表现。投资者将密切关注新团队上任后的具体举措及业绩反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"gpt_icon":0},{"id":"2622227837","title":"宝济药业(02659)2025年度业绩：核心管线快速推进，SJ02完成首批订单交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2622227837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622227837?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:31","pubTimestamp":1774513868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业 公布了截至2025年12月31日止年度的全年业绩。报告期内，公司实现总营收0.49亿人民币，并在研发上持续投入以构建产品的核心竞争力，研发费用达2.48亿人民币。公司三款核心产品分别完成注册、临床和商业化的快速推进。其中，晟诺娃于2025年11月完成首批订单交付，全面开启商业化进程。2026年，公司的主要目标是继续推进多元化的临床产品组合，挖掘产品的临床和商业价值，并在KJ017 NDA获批后实现商业化上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"gpt_icon":0},{"id":"2622745837","title":"《业绩》宝济药业(02659.HK)全年亏损扩大至3.95亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2622745837","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622745837?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 16:30","pubTimestamp":1774513800,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659.HK) 公布截至去年12月底止全年业绩，营业额4,915.6万元人民币(下同)，按年升698%。亏损扩大至3.95亿元，上年同期蚀3.64亿元；每股亏损1.36元。不派息。(ca/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260126145024414_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260126145024414_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512858/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512858/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"gpt_icon":0},{"id":"1149494313","title":"异动解读 | 新药进展伴随风险提示，宝济药业-B盘中大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149494313","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149494313?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425677,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价大幅下挫5.03%，引发市场关注。消息面上，公司早间发布公告，宣布其核心在研新药KJ103用于肾移植脱敏治疗的III期临床试验已完成所有入组受试者的主要随访，并将尽快向国家药监局提交新药上市申请。KJ103是一款全球首创的低免疫原性创新重组免疫球蛋白G降解酶，此前已获得突破性治疗药物认定。然而，公司在同一公告中亦提示风险，明确指出无法保证KJ103最终能够成功开发或实现商业化，并提醒股东及潜在投资者在买卖公司股份时需审慎行事。市场分析认为，尽管新药研发取得阶段性进展，但商业化前景的不确定性引发了投资者的担忧，可能是导致股价盘中承压下跌的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0}],"pageSize":4,"totalPage":22,"pageCount":1,"totalSize":85,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/02659\",params:#limit:6,delay:false,,,undefined,":[]}}